like Pfizer, for example, which is not only cheaper in price and valuation , but also generates more than 6% as a dividend yield, while Eli Lilly generates less than 1%. I understand that Pfizer's performance was very bad, certainly.
This is the argument that pessimists might make , but I actually think the market is largely overlooking it right now, while I can't say the same about Eli Lilly.
Pfizer's management team is already incorporating artificial intelligence to help accelerate drug discovery, which is one of the biggest bullish opportunities that I see with artificial intelligence in the total opportunity value it can add to humanity worldwide.
They're also using artificial intelligence to help optimize manufacturing yields and enhance the effectiveness of its commercial sales force, but I think the bigger opportunity is in drug discovery with these pharmaceutical companies.
Um Fizer, you know, in my opinion, Fizer is like the best like biotech in terms of an overall package valuation dividend wise right now. So, yeah, we're we are a little heavy on it, but I think that's okay. It's only around 4% of the portfolio.
So, Fizer, again, it's like the overall best biotech in terms of valuation and dividend. I think it's a solid biotech uh pharmaceutical play, whatever you want to call it,
